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KEY POINTS 
 
We describe the first successful use of gene therapy in a severely affected adult with Wiskott-Aldrich 
syndrome 
 
Gene therapy is a viable strategy for adult WAS patients with severe chronic disease complications where 
allogeneic transplantation presents 
 
 
 
 
ABSTRACT 
 
Until recently hematopoietic stem cell transplantation was the only curative option for Wiskott-Aldrich 
syndrome (WAS). The first attempts at gene therapy for WAS using a C-retroviral vector improved 
immunological parameters substantially but were complicated by acute leukemia as a result of insertional 
mutagenesis in a high proportion of patients. More recently treatment of children with a state-of-the-art 
self-inactivating lentiviral vector (LV-w1.6 WASp) has resulted in significant clinical benefit without 
inducing selection of clones harbouring integrations near oncogenes. Here, we describe a case of a pre-
splenectomised 30 year old patient with severe WAS manifesting as cutaneous vasculitis, inflammatory 
arthropathy, intermittent polyclonal lymphoproliferation, significant chronic kidney disease and requiring 
long-term immunosuppressive treatment. Following reduced intensity conditioning there was rapid 
engraftment and expansion of a polyclonal pool of transgene-positive functional T cells, and sustained 
gene marking in myeloid and B cell lineages up to 20 months of observation. The patient was able to 
discontinue immunosuppression and exogenous immunoglobulin support, with improvement in vasculitic 
disease and pro-inflammatory markers. Autologous gene therapy using a lentiviral vector is a viable 
strategy for adult WAS patients with severe chronic disease complications and for whom an allogeneic 
procedure could present an unacceptable risk. This trial was registered at ClinicalTrials.gov #NCT01347242. 
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INTRODUCTION 
 
Wiskott-Aldrich syndrome (WAS) is a rare, X-linked, complex primary immunodeficiency disease caused by 
mutations in the WAS gene which encodes a 502-amino acid protein called the Wiskott-Aldrich protein 
(WASp). This regulates the actin cytoskeleton in most hematopoietic lineages and is consequently 
important for normal function of many immunological processes (1-4). Clinical and biological 
manifestations of WAS include microthrombocytopenia, recurrent infections and eczema. Patients also 
display an increased incidence of autoimmunity and are at risk of developing lymphoproliferative disorders 
and lymphoid malignancies (5). A clinical scoring system grades disease severity. Patients with a score of 3-
5 display ‘classical’ WAS usually as a result of null mutations and without definitive treatment these 
patients are not normally expected to survive beyond their third decade (6). For many years the only 
potential curative therapy has been allogeneic hematopoietic stem cell transplantation (HSCT) (7, 8, 9). 
HLA-matched HSCT is today associated with high rates of survival, but HLA-mismatched HSCT may still in 
some cases be accompanied by unacceptable risk even though new immune cell-depletion technologies 
are promising for reduction of graft versus host disease (GvHD) and for accelerating immunological 
reconstitution (10,11). 
 
Gene therapy for Wiskott-Aldrich syndrome was first attempted using a C-retroviral vector (12). This 
approach resulted in a sustained increase in the proportion of WASp-corrected cells in all patients.  
However, 7 of the 9 treated patients developed acute leukemia secondary to viral enhancer-mediated 
insertional mutagenesis. More recently, gene therapy using a self-inactivating lentiviral vector has shown 
promise in children (13, 14). Interim analysis of results from both studies has demonstrated significant 
clinical benefit, and importantly without evidence of oncogenic transformation or sustained clonal 
dominance.  
 
Here, we describe a case of an adult WAS patient (aged 30) for whom a HLA-matched donor could not be 
found and for whom a TCR αβ-depleted haploidentical transplant was deemed to be excessively high risk 
as a result of significant pre-existing disease co-morbidities. The patient was successfully treated on-trial 
(NCT01347242) with gene therapy using the same self-inactivating vector (LV-w1.6 WASp), which had 
previously recruited only children (14).  
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METHODS 
 
Clinical Protocol 
The patient was managed under the care of the clinical immunology and adult bone marrow transplant 
services at the Royal Free London Hospital NHS Foundation Trust (London, England). The patient was 
treated on trial (NCT01347242) sponsored by Genethon (14). The trial protocol was approved by the UK 
Medicines and Healthcare Products Regulatory Agency (MHRA), Gene Therapy Advisory Committee (GTAC) 
and the National Research Ethics Service (NRES). Autologous hematopoietic stem cells were collected from 
mobilised peripheral blood (after cryopreservation of an unmodified back up stem cell harvest) and were 
genetically modified ex vivo during concurrent reduced intensity conditioning of the patient as described 
below.  
 
He received methylprednisolone 70mg (1mg/kg) intravenously on days -8 to -4 as prophylaxis against a 
potential GCSF-induced inflammatory reaction, lenograstim 1.28 million units/kg subcutaneously on days -
7 to -5 followed by plerixafor 0.16mg/kg subcutaneously on days -5 to -4. The patient underwent 
leukapheresis on days -4 and -3. Following confirmation of an adequate starting dose of CD34+ cells, 
conditioning was commenced as per protocol with fludarabine 40mg/m
2
 daily (days -3 to -1) and busulfan 
3.2mg/kg daily (days -3 to -1). No adjuvant serotherapy was given. Due to the patient’s poor renal function 
(EDTA glomerular filtration rate 34ml/min), prophylactic haemodialysis was undertaken on day 0. The 
patient was already established on antibacterial prophylaxis with penicillin V and IVIg following the earlier 
splenectomy and this was continued. Antifungal prophylaxis with voriconazole was commenced on day +3 
and antiviral prophylaxis with acyclovir was started on admission at day -9. Oral trimethoprim-
sulfamethoxazole three times a week was used as Pneumocystis Jirovecii prophylaxis from day -9. 
 
On day 0 transduced autologous CD34+ haematopoietic stem cells were infused. The patient received a 
total dose of CD34+ cells of 3.77 x 10
6/
kg, with a 52% transduction efficiency as determined by flow 
cytometry (gating on CD34
+
, CD45
+
 cells). The transduced cells products were manufactured at Great 
Ormond Street Hospital (London, England). Vector production, biological analyses, CD34+ cell gene 
transfer procedure, integration site analysis and clonality assays were performed as previously described 
(14). The manufacturing process is further outlined below. 
 
Vector Production 
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The clinical LV-w1.6 WASp vector is an advanced generation HIV-derived lentiviral vector pseudotyped 
with VSVg and expressing the full-length WAS cDNA from the WAS gene proximal 1.6kb promoter. The 
clinical vector batch was manufactured at Genethon (Evry, France). Batches were purified, concentrated 
and titered for infectious particles (infectious genomes per millilitre) as previously reported (14).  
 
CD34+ Cell Gene Transfer Procedure 
Cells were cultured at 1 x 10
6
 cells / ml in tissue culture treated flasks (NUNC) in serum-free medium (X-
vivo 20; Lonza) and animal free stem cell factor (SCF, 300ng/ml), Fms-like tyrosine kinase 3 ligand (Flt3, 
300ng/ml), thrombopoietin (TPO, 100ng/ml) and IL-3 (20ng/ml) (all from Peprotech). G-CSF and 
Plerixafluor mobilised peripheral blood was collected from the patient by apheresis. Immunomagnetic 
beads and an immunomagnetic separation device were used to positively select CD34+ cells (CliniMACS, 
Miltenyi Biotec). CD34+ cells were seeded in serum-free medium (X-Vivo20, Lonza), supplemented with 1% 
human albumin solution (HAS) and cytokines IL-3, SCF, Flt3, TPO. All cytokines (Peprotech) and culture 
reagents were approved for ex vivo clinical use.  Cells were then incubated at 37ºC, 5% CO
2
. After 17 hours 
total pre-stimulation, cells were returned to pre-coated tissue culture flasks and transduced twice with 
LV.w1.6 WASp (2 x 10
8
 infectious particles per ml), for 17 hours each time. Washed cells were then 
resuspended (at 3x10
6
 CD34+/ml) in 2% human albumin in a sterile bag for infusion to the patient. 
Reserved cell aliquots were cultured for 14 days afterwards to assess proviral integration by quantitative 
PCR and WASp expression by flow cytometry. 
 
Analysis of thymic output  
Signal joint T-cell receptor excision circles (sjTREC) were assessed using quantitative real-time polymerase 
chain reaction (qRT-PCR). sjTREC content was expressed in copies per 10
5
 peripheral blood mononuclear 
cells (PBMCs) (control range, 150-2500/10
5
 PBMCs).  
 
T cell repertoire analysis by TCR spectratyping 
Clonality of T cells was monitored using T-cell receptor TCR V beta spectratyping. Briefly, the CDR3 region 
of the beta chain was amplified from patient cDNA using a single constant region primer with 24 variable 
region primers. A fluorescent run-off reaction was then carried out and the products were run on a 3500xL 
Genetic Analyzer. Subsequent spectratypes were analysed using GeneMapper 5 software and flow analysis 
used the IOTest Beta Mark assay (Beckman Coulter). 
 
Analysis of vector copy number  
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Vector copy number per cell was measured by quantitative PCR detection of the vector’s HIV psi sequence 
with normalisation against the copy number of the albumin gene. Lymphoid and myeloid subpopulations 
were sorted by flow cytometry using their corresponding fluorescence-labelled monoclonal antibodies.  
 
Analysis of integration site distributions  
Detailed methods are as described previously (15-19). Briefly, DNA was randomly sheared via 
ultrasonication and DNA linkers were ligated to the cleaved ends. DNA fragments were then amplified by 
ligation-mediated PCR, using primers annealing to the LTR of the vector and to the linker to isolate and 
enrich for host-vector junctions. PCR was performed in quadruplicate for each sample. Amplicons were 
sequenced using an Illumina MiSeq instrument. Sequence reads were aligned to the human genome (hg18) 
to identify vector integration sites. The distance between the vector-host junction and the breakpoint of 
the DNA produced by shearing can be used to differentiate distinct cells with the same integration site. 
Since the DNA is randomly sheared via sonication prior to amplification, these DNA fragment lengths, or 
“sonic lengths” (19), can be used to estimate the abundance of cell clones, avoiding the need to estimate 
based on read counts acquired after biased amplification and sequencing. Cells harboring the same 
integration site can be differentiated and directly counted by sonic length and then summed to estimate 
the abundance (“sonic abundance”) of the integration site within the population. DNA sequence reads 
used in this study are available at the National Center for Biotechnology Information SRA under accession 
numbers BioProject ID PRJNA387194. 
 
Analysis of WASp protein expression  
WASp expression in PBMC and lymphocytes was analysed by flow cytometry on a FACSCalibur cell analyser 
(BD Biosciences) using the Simultest CD3 FITC/CD16+CD56 PE and CD19PECy7 antibodies (BD Biosciences) 
for lymphocyte characterisation and the WASp (IgG
2a) 
5A5 clone (BD Biosciences) for WASp intracellular 
staining. For Western-blotting, platelets were purified from EDTA-blood by serial centrifugation (15min at 
800rpm with no brake followed by 15min at 1800rpm). Protein extracts from the pelleted platelets were 
separated on a 10% SDS-PAGE gel, and WASp was detected using the WASp (D-1) antibody (Santa Cruz 
Biotechnology). 
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RESULTS  
 
Case Presentation 
The patient first presented aged 3 years with easy bruising and epistaxis. Thrombocytopenia and small 
platelets on peripheral blood film examination raised the suspicion of WAS. Western blotting for WASp and 
gene sequencing were performed later and confirmed the clinical diagnosis. Sanger sequencing confirmed 
a T>C mutation 2 bases into the 5’ splice site of intron9 of the WASP gene (IVS9+2 T to C). This mutation is 
predicted to disrupt the splicing of exon 9 resulting in the activation of a cryptic splice site and the 
insertion of the 115bp 5' segment of intron 9 causing a frameshift and a termination codon within the 
inserted segment (20-22). The patient is of Asian British Pakistani ethnicity and there were no other 
documented cases in the patient’s family.  After episodes of spontaneous bleeding secondary to 
thrombocytopenia later in childhood, a splenectomy was performed, which resulted in normalisation of 
platelet numbers. In mid-childhood the patient began to develop autoimmune and inflammatory 
phenomena, including recurrent episodes of uveitis, cutaneous leucocytoclastic vasculitis with skin 
ulceration, episodic synovitis, thyroiditis and non-malignant lymphoproliferative disease. These episodes 
were accompanied by gross elevation in acute phase proteins.  The vasculitis in particular was increasingly 
difficult to control and persisted throughout adolescence. Immunosuppression with varying combinations 
of steroids, colchicine, methotrexate, cyclophosphamide, cyclosporin, mycophenolate mofetil and 
rituximab failed to fully control the patient’s symptoms or to normalise inflammatory markers.  
 
Due to the patient’s increasingly aggressive autoinflammatory phenotype he was referred for 
consideration of HSCT. No HLA matches were identified within his immediate family. A matched unrelated 
donor was identified but transplant was delayed by recurrent attacks of vasculitis, uveitis and synovitis 
during which time the donor was deleted from the registry. Further unrelated donor searches proved 
unsuccessful.  
 
The clinical picture was further complicated by progressive deterioration in renal function. A renal biopsy 
was performed that showed features of neutrophil-rich infiltrating tubulointerstitial disease, reminiscent 
of reflux nephropathy, but with no previous history of recurrent urinary tract infections in childhood. No 
changes consistent with calcineurin inhibitor toxicity were identified and no deposition of immunoproteins 
observed. Creatinine clearance fell to 24ml/min. Following the recent success of the gene therapy trial in 
children it was suggested that the patient could benefit from treatment using a similar protocol (14).  
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WAS severity score prior to gene therapy was 5 reflecting his severe disease phenotype and his 
Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score was 8 indicating a high-risk 
of treatment-related mortality (23). Written informed consent was obtained from the patient after 
explanation of the risks and benefits and discussion of other treatment options available. 
 
At a follow up of 20 months post gene therapy the patient is well, with normal peripheral blood counts, 
stable renal function (estimated GFR 41ml/min), no significant episodes of vasculitis or arthritis and free of 
major immunosuppression. Importantly, he has now completed his education and works part time, neither 
of which were possible prior to treatment because of illness. Normal CD4+, CD8+ and NK cell counts were 
reached at 12 months post therapy (Table 1). T cell proliferation in response to phytohemagglutinin (PHA) 
and anti-CD3/anti-CD28 antibody stimulation also normalised. It should be noted that in addition to an 
intrinsic suppression as a result of long-standing disease, the patient’s pre-GT PHA responses were likely 
also blunted by the anti-proliferative immunosuppressant mycophenylate mofetil (MMF). Long term IVIg 
supplementation was withdrawn 10 months after gene-therapy as endogenous IgG, A and M (5.7, 1.4 and 
0.2 g/L respectively) levels were rising. There was an excellent serological response to tetanus vaccine 
(Table 1).  Response to a single conjugated pneumococcal vaccine (at 22 months post GT) was partial with 
a 10-fold increase in total anti-pneumococcal specific IgG after 2 vaccinations, but to a restricted repertoire 
(3/13 serotypes). Platelet counts remained stable, within the normal range after recovery from 
myelosuppression. 
 
The patient demonstrated robust and multi-lineage engraftment in peripheral blood of gene-corrected 
cells, which was sustained to the latest time point analysed (20 months post gene therapy). T cells 
exhibited the highest level of gene marking at 12 months compared to other lineages as observed in 
previous studies, although gene marking in myeloid cells was also sustained at approximately 10% 
suggesting that transduced HSCs were successfully engrafted (Figure 1). This was supported by evidence 
for persistent gene marking in purified bone marrow CD34
+
 cells analysed 16 months after treatment, with 
an observed vector copy number of 0.34 (Figure 1). B cell marking was also very robust as observed in 
some patients in previous studies (14 [see patients 2, 4 and 6]). All lineages exhibited restoration of WASp 
expression (Figure 2A). Western blot analysis confirmed low level expression of WASp in the platelet 
fraction at 12 months post gene therapy suggesting that a contribution to the platelet compartment was 
also now derived from engrafted HSCs (Figure 2B). No platelet transfusions were given at any time. 
Prominent WASp expression was detected in purified naïve CD4
+
 and CD8
+
 T cells at 20 months post GT 
For personal use only.on July 28, 2017. by guest  www.bloodjournal.orgFrom 
MORRIS et al                                               GENE THERAPY IN ADULTHOOD FOR SEVERE WAS 
 
9
(Figure 2C). In addition, a sustained improvement in T cell repertoire and thymic output were observed in 
both CD4+ and CD8+ T cell compartments post GT (Figure 3A and B). 
 
The distributions of integration site frequencies are summarized in stacked bar graphs in Figure 4.  Both 
the statistics summarized in the Table 2 and the stacked bar graphs indicate highly polyclonal cell 
populations. Low Gini coefficients, high Shannon indices, and high UC50 values (15, 16) are reported across 
samples, indicating polyclonality (Table 2).  In Figure 4, most of the integration sites sampled are low 
abundance (colored grey in the figure). No unique clone accounts for greater than 2.5% of the total data 
for any given sample. Further, no integration site within 100 kb of a gene previously associated with 
adverse events in gene therapy (LMO2, CCND2, MECOM) accounts for greater than 0.4% of the total 
abundance in any cell type at any time point. The polyclonality of integration sites identified in this adult 
patient is comparable to populations seen in pediatric patients treated with the same vector (LV-w1.6 
WASp) at corresponding time points (14). More detailed analysis of integration site distributions and 
relative clonal abundance is included in the supplementary data (supplementary data, Figure S2).  
 
Several short-lived adverse events were noted post gene therapy including disseminated shingles (6 
months post therapy), transient lymphadenopathy and pyrexia of unknown origin (7 months post therapy), 
scleritis requiring topical steroids (10 months post therapy), acute acne associated with an inflammatory 
ulcer on the jawline (Supplementary data, Figure S1) and transient alopecia areata (fungal culture 
negative). A lymph node biopsy performed at the time when lymphadenopathy was present showed 
reactive changes only. Histology of the inflammatory facial lesion was suggestive of 
pseudoepitheliomatous hyperplasia with a dense inflammatory infiltrate of lymphocytes, plasma cells, 
eosinophils and neutrophils. No atypical mycobacteria or other pathogens were identified, and the lesion 
resolved with broad-spectrum oral antimicrobial therapy. 
 
In view of his inflammatory disease manifestations, we measured serum cytokine levels pre- and 18 
months post- gene therapy. Compared with healthy controls, significantly elevated lymphoid and myeloid- 
derived pro-inflammatory cytokines were observed prior to treatment (Figure 5A and 5B). Almost all were 
substantially lower post therapy, although some remained elevated, notably the pro-inflammatory 
cytokines IL-18 and IFN-g which are primarily derived from myeloid cells. Serum C-reactive protein (CRP) 
levels, which were very elevated prior to treatment despite MMF and steroids, also improved over time, 
possibly enhanced by addition of the anti-inflammatory drug, colchicine (Figure 6).  
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DISCUSSION 
 
It is reassuring that in this adult patient the same pattern of reconstitution was observed as seen in 
paediatric patients (LV-w1.6 WASp) (13, 14), suggesting that potential for T cell repertoire recovery in older 
patients is well-preserved. In keeping with results of previous gene therapy trials gene marking was higher 
in the lymphoid compared to the myeloid compartment, which is likely due to the previously described 
survival advantage conferred by WASp expression in mature lymphoid cells in particular (14, 24). This 
phenomenon has also been observed in WAS patients who have undergone allogeneic HSCT (7). 
 
The re-occurrence of transitory inflammatory complications post gene therapy is interesting as lymphoid 
reconstitution appears excellent. One episode of acute acne was associated with pseudoepitheliomatous 
hyperplasia in a facial lesion, and bore some resemblance to features of the rare inherited 
autoinflammatory PAPA syndrome caused by mutations in PSTPIP1, a cytoskeletal adaptor known to 
regulate WASp in macrophages (25). Both pseudoepitheliomatous hyperplasia and PAPA syndrome are 
associated with increased production of IL1B family pro-inflammatory cytokines including IL-18 (26, 27). It 
therefore seems likely that there is a persistent inflammasome–mediated mechanism for residual 
inflammation which may therefore reflect presence of significant numbers of non-transduced myeloid 
cells. Interestingly, addition of colchicine successfully suppressed further inflammation.  
 
This is the first report of successful gene therapy in an adult with severe WAS. There was rapid 
engraftment and expansion of a polyclonal pool of functional T cells, and sustained gene marking in 
myeloid and B cell lineages up to 20 months of observation. As described, apart from colchicine the patient 
was able to discontinue all immunosuppression and has recently been withdrawn from exogenous 
immunoglobulin support. Longer follow-up and testing in other patients will be required to confirm these 
early results. Whislt we recognise that recent developments in reducing the toxicities associated with 
mismatched Allo HSCT may impact on the choice between gene therapy or Allo HSCT, the limited side 
effects associated with the gene therapy procedure and the benefits seen in this case demonstrate that 
gene therapy using a lentiviral vector may be a viable alternative strategy for adult WAS patients with 
severe chronic disease-related complications, for whom an allogeneic HSCT procedure presents an 
unacceptable risk.  
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TABLES 
 
  Pre  
Gene Therapy 
16 months  
post  
Healthy control ranges 
for 3 day stimulation 
T Cell Proliferation Spontaneous (cpm) 103 115  
 
PHA (cpm) 2490 50349 18906 – 417388 
 
aCD3 (cpm) 226 22699 187 – 122682 
 
aCD3/aCD28 (cpm) 2186 52068 1202 – 213904 
 
    
  Pre Gene 
Therapy 
 
6 months  
post  
11 months 
post  
16 months 
post 
Lymphocyte 
Subsets 
Total lymphocytes  
(x 10
9
/ml) 
[Normal range: 1.0-2.8] 
0.572 2.251 1.469 1.11 
 
CD3 (x 10
9
/ml) 
[Normal range: 0.7-2.1] 
0.518 1.389 0.789 0.723 
 
CD4 (x 10
9
/ml) 
[Normal range: 0.3-1.4] 
0.414 0.62 0.407 0.409 
 
CD8 (x 10
9
/ml) 
[Normal range: 0.2-0.9] 
0.105 0.408 0.252 0.23 
 
CD19 (x 10
9
/ml) 
[Normal range: 0.1-0.5] 
0.027 0.408 0.407 0.409 
      
  Pre Gene 
Therapy 
 
Post GT 
Pre-vaccination 
Post GT 
Post-vaccination 
Vaccination 
Responses 
Total Pneumococcus 
titres (mg/L) 
[protective levels 
>20mg/L] 
On 
immunoglobulin 
replacement 
therapy 
4 43 
 Pneumococcus serotype 
specific responses  
[protective levels > 
0.35mg/L] 
On 
immunoglobulin 
replacement 
therapy 
ND Protective responses 
against 3/13 serotypes  
 Tetanus Toxoid IU/ml 
[protective levels 0.1 -0.7 
IU/ml] 
On 
immunoglobulin 
replacement 
therapy 
0.14 2.51 
 
Table 1: T cell proliferation assays, lymphocyte subsets and vaccination responses pre and post gene 
therapy. 
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Timepoint Cell Type Total Reads Inferred 
Cells 
Unique Sites S.chao1 Gini Shannon UC50 
6 months B cells 1036782 4639 3891 19855 0.1204 8.2045 1647 
 Monocytes 222125 329 248 893 0.1950 5.4176 86 
 Neutrophils 803235 2018 1522 6981 0.1866 7.2162 552 
 NK cells 1111841 3000 2128 7757 0.1751 7.5657 795 
 PBMC 684175 2115 1386 4844 0.2668 7.0254 381 
 T cells 1038680 5685 3089 10815 0.3937 7.4591 539 
         
12 months B cells 925356 2197 1745 7702 0.1438 7.3907 701 
 Monocytes 347061 351 242 1970 0.2517 5.3341 69 
 Neutrophils 558321 729 492 1866 0.2496 6.0383 139 
 NK cells 507007 697 469 1865 0.2413 6.0123 135 
 PBMC 463071 2076 1744 7513 0.1387 7.3578 720 
 T cells 981471 3142 2089 9696 0.2748 7.3678 574 
 
Table 2. Table summarizing the distribution and relative abundance of integration sites isolated from 
several cell types at 6 and 12 months after therapy.  
The table summarizes the sample metadata and sequencing data, and reports summary statistics for each 
sample. To summarize the data, the total number of sequence reads (TotalReads), the inferred number of 
cells with integrated vector identified (InferredCells), and number of unique integration sites identified 
(UniqueSites) are shown. Statistics to summarize population structure are also presented. The Chao1 
analysis (S.chao1) is an estimate of minimum population size (28). The Gini coefficient is a measure to 
represent distribution. Here, a value of 0 indicates even distribution of integration sites while values 
increasing towards 1 demonstrate increasing inequality of integration site abundance within the 
population. The Shannon index summarizes diversity by accounting for both abundance and evenness 
among the integration sites in the cell population. Lastly, the UC50, a new metric, indicates the number of 
unique clones contributing the top 50% of the sample’s total abundance (16). 
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FIGURE LEGENDS 
 
Figure 1. Persistent gene-marking post gene therapy. 
Longitudinal results of gene marking in peripheral blood and bone marrow after gene therapy as expressed 
by vector copy number per peripheral blood mononuclear cell, peripheral blood purified cell lineage or 
bone marrow derived CD34
+
 cell.  
 
Figure 2. Correction of WASp expression post gene therapy. 
(A) WASp protein expression in T cells, B cells and NK cells; (B) Western blot demonstrating WASp 
expression in patient’s platelets compared to healthy control [con = healthy control]. NB, patient received 
no platelet transfusions at any time; (C) WASp protein expression in purified naïve CD4
+
 and CD8
+
 T cells at 
20 months post GT. 
 
Figure 3. Improvement of T cell repertoire and thymic output post gene therapy. 
(A) T cell repertoire analysis by TCR spectratyping pre and post GT in CD4
+ 
and CD8
+
 T cells; (B) sjTREC 
content in CD4
+
 (red line) and CD8
+ 
(blue line) T cells (dotted line corresponds to 10
th
 centile for patient’s 
age group). 
 
Figure 4. Relative abundance of cell clones. 
Stacked bar graphs showing the relative sonic abundance, scaled as a proportion of the total. Data are 
separated by cell type with side-by-side comparison of time points for visualization of longitudinal changes. 
The 10 most abundant integration sites for each cell type are emphasized by uniquely colored bars and 
named by the nearest gene, indicated in the ‘GeneNames’ key. The genes are marked with symbols to 
indicate further information about the integration site/gene: * (asterisk) indicates the site is within a 
transcription unit, ~ (tilde) indicates the site is within 50kb of a cancer related gene, ! (exclamation point) 
indicates the gene is associated with lymphoid cancers in humans. The remaining low abundance 
integration sites are indicated in grey (LowAbund). The cutoff values for binning clones as low abundance 
are indicated at the top of each cell type panel.  
 
Figure 5. Reduction in serum cytokine levels post gene therapy.  
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Multiple cytokines associated with predominantly lymphoid (A, upper panel) and myeloid (B, lower panel) 
cells were measured by luminex in the patient pre- and 18 months post- gene therapy (Pt Pre and Pt Post) 
and compared with healthy controls (HC1 and HC2). 
 
Figure 6. Clinical course pre and post gene therapy showing a reduction in serum C-reactive protein (CRP) 
over time.  
Key: *prednisolone 30mg daily x 3 days; ankle swelling and cutaneous tenderness, ?vasculitis  
**prednisolone 30mg daily x 4 days; admitted with lymphadenopathy, pyrexia of unknown origin 
***prednisolone 30mg daily x 3 days; foot swelling and cutaneous tenderness (self medicated)  
****prednisolone 30mg daily x 3 days; cutaneous tenderness and nodules (self medicated) 
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